Fellowship Focus: Elevating Pediatric Medication Safety Through Data, AI, and Collaboration
April 28th 2025Ochsner Children’s Hospital, in partnership with ISMP, has launched a fellowship to advance pediatric medication safety through hands-on training in key competencies, national safety strategies, interdisciplinary collaboration, and innovative tools such as AI and data dashboards.
Read More
AACR 2025: Off-the-Shelf CAR NK Therapy SENTI-202 Shows Potential for Complete Remission in R/R AML
April 27th 2025Interim results from the phase 1 SENTI-202-101 trial show that SENTI-202, a logic-gated, off-the-shelf chimeric antigen receptor natural killer (CAR NK) cell therapy, achieved complete remission in 4 patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
Read More
JAK1 Inhibitor NS-229 Granted FDA Orphan Drug Designation to Treat Allergic Autoimmune Condition
April 25th 2025NS-229 is a Janus kinase 1 (JAK1) inhibitor being investigated in eosinophilic granulomatosis with polyangiitis, a rare autoimmune condition that can cause severe allergic and asthmatic symptoms through inflammation of nerve cells.
Read More